IL-10 Dependent Suppression of Type 1, Type 2 and Type 17 Cytokines in Active Pulmonary Tuberculosis

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Kumar, Nathella Pavan ^a,b   Gopinath, Venugopal ^a,b   Sridhar, Rathinam ^c   Hanna, Luke E ^b   Banurekha, Vaithilingam V ^b   Jawahar, Mohideen S ^b   Nutman, Thomas B ^d   Babu, Subash ^a,d  

^a National Institutes of Health International Center for Excellence in Research   (India)

^b NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^c Government Stanley Hospital   (India)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CULTURE FILTRATE PROTEIN 10; CYTOKINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOREGULATION; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL; TUBERCULOUS LYMPHADENITIS;

ADULT; AGED; ANTIGENS, BACTERIAL; CYTOKINES; FEMALE; HUMANS; IMMUNOMODULATION; INTERLEUKIN-10; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84875461384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059572     Document Type: Article

References (34)

1. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A, (2011) Immunological biomarkers of tuberculosis. Nat Rev Immunol 11: 343-354.
2. Handa U, Mundi I, Mohan S, (2012) Nodal tuberculosis revisited: a review. J Infect Dev Ctries 6: 6-12.
3. Cooper AM, (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393-422.
4. Holland SM, (2007) Interferon gamma, IL-12, IL-12R and STAT-1 immunodeficiency diseases: disorders of the interface of innate and adaptive immunity. Immunol Res 38: 342-346.
5. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104.
6. Khader SA, Cooper AM, (2008) IL-23 and IL-17 in tuberculosis. Cytokine 41: 79-83.
7. Ellner JJ, (2010) Immunoregulation in TB: observations and implications. Clin Transl Sci 3: 23-28.
8. Redford PS, Murray PJ, O'Garra A, (2011) The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 4: 261-270.
9. Ernst JD, (2012) The immunological life cycle of tuberculosis. Nat Rev Immunol 12: 581-591.
10. Lalvani A, Pareek MA, (2010) 100 year update on diagnosis of tuberculosis infection. Br Med Bull 93: 69-84.
11. Kaufmann SH, (2001) How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 1: 20-30.
12. Flynn JL, (2006) Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 8: 1179-1188.
13. Jacobs M, Samarina A, Grivennikov S, Botha T, Allie N, et al. (2007) Reactivation of tuberculosis by tumor necrosis factor neutralization. Eur Cytokine Netw 18: 5-13.
14. Kahnert A, Seiler P, Stein M, Bandermann S, Hahnke K, et al. (2006) Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur J Immunol 36: 631-647.
15. Harris J, De Haro SA, Master SS, Keane J, Roberts EA, et al. (2007) T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 27: 505-517.
16. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
17. Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, et al. (2005) IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 175: 788-795.
18. Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, et al. (2007) IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 178: 3786-3796.
19. Wozniak TM, Ryan AA, Triccas JA, Britton WJ, (2006) Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun 74: 557-565.
20. Dheda K, Chang JS, Lala S, Huggett JF, Zumla A, et al. (2008) Gene expression of IL17 and IL23 in the lungs of patients with active tuberculosis. Thorax 63: 566-568.
21. Pasquinelli V, Townsend JC, Jurado JO, Alvarez IB, Quiroga MF, et al. (2009) IFN-gamma Production during Active Tuberculosis Is Regulated by Mechanisms That Involve IL-17, SLAM, and CREB. J Infect Dis 199: 661-665.
22. Peng MY, Wang ZH, Yao CY, Jiang LN, Jin QL, et al. (2008) Interleukin 17-producing gamma delta T cells increased in patients with active pulmonary tuberculosis. Cell Mol Immunol 5: 203-208.
23. Scriba TJ, Kalsdorf B, Abrahams DA, Isaacs F, Hofmeister J, et al. (2008) Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 180: 1962-1970.
24. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A, (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822.
25. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al. (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146: 3444-3451.
26. Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, et al. (1993) Cytokine production at the site of disease in human tuberculosis. Infect Immun 61: 3482-3489.
27. Almeida AS, Lago PM, Boechat N, Huard RC, Lazzarini LC, et al. (2009) Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol 183: 718-731.
28. Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deutekom H, et al. (1999) Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol 115: 110-113.
29. Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, et al. (2000) IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 105: 1317-1325.
30. Gong JH, Zhang M, Modlin RL, Linsley PS, Iyer D, et al. (1996) Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect Immun 64: 913-918.
31. Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, et al. (1994) T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 94: 2435-2442.
32. Hirsch CS, Ellner JJ, Blinkhorn R, Toossi Z, (1997) In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta. Proc Natl Acad Sci U S A 94: 3926-3931.
33. Hirsch CS, Hussain R, Toossi Z, Dawood G, Shahid F, et al. (1996) Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci U S A 93: 3193-3198.
34. Toossi Z, Gogate P, Shiratsuchi H, Young T, Ellner JJ, (1995) Enhanced production of TGF-beta by blood monocytes from patients with active tuberculosis and presence of TGF-beta in tuberculous granulomatous lung lesions. J Immunol 154: 465-473.